Stifel Financial Corp Buys 10,892 Shares of Sanofi (NASDAQ:SNY)

Stifel Financial Corp increased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 562,547 shares of the company's stock after acquiring an additional 10,892 shares during the quarter. Stifel Financial Corp's holdings in Sanofi were worth $32,420,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Tidal Investments LLC acquired a new stake in shares of Sanofi in the 1st quarter worth about $228,000. Lantz Financial LLC boosted its position in shares of Sanofi by 23.2% during the second quarter. Lantz Financial LLC now owns 8,054 shares of the company's stock worth $391,000 after buying an additional 1,518 shares during the period. Peoples Bank KS increased its position in Sanofi by 8.1% in the 2nd quarter. Peoples Bank KS now owns 18,160 shares of the company's stock valued at $881,000 after acquiring an additional 1,360 shares during the period. Sequoia Financial Advisors LLC raised its stake in Sanofi by 9.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 21,090 shares of the company's stock valued at $1,023,000 after acquiring an additional 1,883 shares in the last quarter. Finally, Cooper Financial Group acquired a new position in Sanofi during the 2nd quarter worth $238,000. Institutional investors own 10.04% of the company's stock.

Sanofi Trading Down 0.1 %

Shares of Sanofi stock traded down $0.05 on Friday, reaching $48.46. 1,590,336 shares of the company were exchanged, compared to its average volume of 2,300,876. The firm has a market capitalization of $122.98 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 1.22 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a fifty day moving average price of $51.90 and a 200-day moving average price of $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same period last year, the business earned $2.55 earnings per share. Sanofi's quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on SNY. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a report on Friday. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.